There's been a major selloff in SI-BONE, Inc. (NASDAQ:SIBN) shares in the week since it released its quarterly report, with the stock down 20% to US$12.44. It looks like the results were pretty good overall. While revenues of US$40m were in line with analyst predictions, statutory losses were much smaller than expected, with SI-BONE losing US$0.16 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for SI-BONE

Taking into account the latest results, the current consensus from SI-BONE's nine analysts is for revenues of US$193.8m in 2025. This would reflect a sizeable 23% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 31% to US$0.62. Before this latest report, the consensus had been expecting revenues of US$194.7m and US$0.75 per share in losses. Although the revenue estimates have not really changed SI-BONE'sfuture looks a little different to the past, with a cut to the loss per share forecasts in particular.

The average price target held steady at US$23.22, seeming to indicate that business is performing in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values SI-BONE at US$32.00 per share, while the most bearish prices it at US$18.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 18% growth on an annualised basis. That is in line with its 19% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.2% per year. So it's pretty clear that SI-BONE is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$23.22, with the latest estimates not enough to have an impact on their price targets.